TC BioPharm Holdings PLC (TCBP)
$0.49
$-0.01
(-2.04%)
As on 17-Apr-2025 09:30EDT
Market cap
$0 Mln
Revenue (TTM)
$-- Mln
P/E Ratio
--
P/B Ratio
0.1
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-- Mln
-
ROE
-5.8 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.2
-
Debt to Equity
0.7
-
Book Value
$0
-
EPS
$-0
-
Face value
--
-
Shares outstanding
512,992
5 Years Aggregate
CFO
£-40.82 Mln
EBITDA
£-45.67 Mln
Net Profit
£-34.02 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
TC BioPharm Holdings PLC (TCBP)
| -95.3 | -71.7 | -93.8 | -99.8 | -99.4 | -- | -- |
|
BSE Sensex*
| -10.4 | -1.0 | -7.8 | -7.7 | 6.7 | 8.3 | 11.1 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
|---|---|---|
|
TC BioPharm Holdings PLC (TCBP)
| -97.9 | -99.6 |
|
S&P Small-Cap 600
| 7.0 | 13.9 |
|
BSE Sensex
| 8.1 | 18.7 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Shareholding Pattern
View DetailsAbout TC BioPharm Holdings PLC (TCBP)
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on the development of immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an allogeneic unmodified... gamma-delta T cell therapy product under Phase 2/3 trails for the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat viral infections as well as cancers. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. Read more
-
CEO & Director
Mr. Bryan L. Kobel
-
CEO & Director
Mr. Bryan Leland Kobel
-
Headquarters
Motherwell
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for TC BioPharm Holdings PLC (TCBP)
What is the current share price of TC BioPharm Holdings PLC (TCBP) Today?
The share price of TC BioPharm Holdings PLC (TCBP) is $0.49 (NASDAQ) as of 17-Apr-2025 09:30 EDT. TC BioPharm Holdings PLC (TCBP) has given a return of -99.36% in the last 3 years.
What is the current PB & PE ratio of TC BioPharm Holdings PLC (TCBP)?
Since, TTM earnings of TC BioPharm Holdings PLC (TCBP) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-100.10
|
220.19
|
|
2022
|
-5.11
|
20.28
|
|
2021
|
--
|
--
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
What is the 52 Week High and Low of TC BioPharm Holdings PLC (TCBP)?
The 52-week high and low of TC BioPharm Holdings PLC (TCBP) are Rs -- and Rs -- as of 28-May-2026.
What is the market cap of TC BioPharm Holdings PLC (TCBP)?
TC BioPharm Holdings PLC (TCBP) has a market capitalisation of $ 0 Mln as on 17-Apr-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in TC BioPharm Holdings PLC (TCBP)?
Before investing in TC BioPharm Holdings PLC (TCBP), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.